The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was well tolerated.

Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients with lower vision, according to a speaker here. During a presentation at ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

It's a daycare procedure and doesn't require hospitalisation. However, it is an expensive treatment. Will my health insurance ...

Highlighting the event is the immersive simulation, “Seeing Beyond the Ordinary and Repairing Damages,” led by world-renowned ...

Diabetes affects millions worldwide, and while most know about its impact on blood sugar and organ health, vision loss ...

The implementation of AIDRSS offers transformative implications for DR screening in India, particularly in rural and ...

Diabetes extends far beyond blood sugar management, affecting vital organs throughout the body. This chronic condition, ...

About AXPAXLI AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI) is an investigational, bioresorbable, hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase ...

Experiencing fatigue, blurred vision, and unexplained weight loss, a young man sought medical consultation and was informed ...

Insurance coverage for intravitreal injections, an essential treatment for diabetic retinopathy, depends on the specific terms and conditions of an individual’s health insurance policy.